Huang, X.-S.; Tian, R.-R.; Ma, M.-D.; Luo, R.-H.; Yang, L.-M.; Peng, G.-H.; Zhang, M.; Dong, X.-Q.; Zheng, Y.-T.
Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment. Pharmaceuticals 2022, 15, 338.
https://doi.org/10.3390/ph15030338
AMA Style
Huang X-S, Tian R-R, Ma M-D, Luo R-H, Yang L-M, Peng G-H, Zhang M, Dong X-Q, Zheng Y-T.
Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment. Pharmaceuticals. 2022; 15(3):338.
https://doi.org/10.3390/ph15030338
Chicago/Turabian Style
Huang, Xu-Sheng, Ren-Rong Tian, Meng-Di Ma, Rong-Hua Luo, Liu-Meng Yang, Guang-Hui Peng, Mi Zhang, Xing-Qi Dong, and Yong-Tang Zheng.
2022. "Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment" Pharmaceuticals 15, no. 3: 338.
https://doi.org/10.3390/ph15030338
APA Style
Huang, X.-S., Tian, R.-R., Ma, M.-D., Luo, R.-H., Yang, L.-M., Peng, G.-H., Zhang, M., Dong, X.-Q., & Zheng, Y.-T.
(2022). Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment. Pharmaceuticals, 15(3), 338.
https://doi.org/10.3390/ph15030338
